A study aimed to elucidate the relationship between chemotherapy-induced oral mucositis (OM) and oral microbiota and establish preventive measures.

2023 Fiscal Year Final Research Report

• Project/Area Number: 19K07886
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 52010:General internal medicine-related
• Research Institution: University of Toyama
• Principal Investigator: Kajiura Shinya 富山大学, 学術研究部医学系, 講師 (70456383)
• Project Period (FY): 2019-04-01 – 2024-03-31
• Keywords: 化学療法 / 口内炎 / 口腔内細菌叢 / 乳酸菌製剤 / がん悪液質 / アナモレリン / プロバイオテクス

Outline of Final Research Achievements

We compared 16S rRNA analysis between chemotherapy-induced oral mucositis (OM) patients and non-OM patients to identify bacteria more prevalent in non-OM patients. Despite conducting retrospective analysis on chemotherapy-induced OM and supportive care, no correlation was found between lactobacillus preparations and OM. However, secondary analysis revealed that Anamorelin hydrochloride, a novel treatment for cancer cachexia, showed potential efficacy with prolonged administration during chemotherapy but not feasible in cases where chemotherapy became challenging. These findings were presented at the 5th International Conference on Palliative Care and accepted for publication in the Journal of Palliative Medicine.

Free Research Field

緩和医療

Academic Significance and Societal Importance of the Research Achievements

化学療法起因性口内炎と口腔内細菌叢について、口内炎非発症者に多い細菌を同定したことで、化学療法起因性口内炎と口腔内細菌叢との関連が示唆される学術的意義がある。乳酸菌製剤によるプロバイオテクスによる化学療法起因性口内炎の治療に結びつくと推定したが、本後ろ向き研究では乳酸菌製剤と口内炎に相関は指摘できなかったが、今後の前向き研究の課題を得る意義はあった。副次的な検討ではあるが、がん悪液質の新規治療薬であるアナモレリン塩酸塩は、化学療法中にこそ投与が検討されるべきであるという学術的社会的意義のある結果が得られた。